NYR listing date, page-5

It's about 30 ish per cent with the dilution. I'm wondering whether news of these events will occur this month?

(1) To help elevate the Company’s profile in the PCSK9
drug development field, Nyrada has put together a
scientific paper of its successful research and
development results and is in the process of
submitting the paper to a well-respected, peer reviewed journal. The paper is anticipated to be
published towards the end of 2019.


(2) Recently, the Company has identified another
compound that it believes also could be efficacious
in the treatment of neuropathic pain. Both this
newly identified compound and NYX-205 are now set
to go head-to-head in an animal model of sciatica.
Nyrada has engaged with the global research
organisation Shanghai ChemPartners to conduct a
pre-clinical study on the efficacy of both compounds
in the treatment of sciatic nerve-associated pain.
One well-established animal model of sciatica is
called the Chronic Constriction Injury (CCI) model.
Shanghai ChemPartner will test both compounds in
the CCI model to determine what the likely success
of either compound in the treatment of neuropathic
pain would be. The readout from this study is
anticipated in the second half of 2019 and will
determine which compound is taken further into
pre-clinical testing.